Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
Mamishin K, Naito Y, Nomura S, Ogawa G, Niguma K, Baba K, Sakaeda S, Nakajima H, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Kawasaki T, Mukohara T. Mamishin K, et al. Among authors: kogawa t. Anticancer Res. 2021 Dec;41(12):6217-6224. doi: 10.21873/anticanres.15441. Anticancer Res. 2021. PMID: 34848476
Thrombocytosis as a prognostic factor in inflammatory breast cancer.
Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Harano K, et al. Among authors: kogawa t. Breast Cancer Res Treat. 2017 Dec;166(3):819-832. doi: 10.1007/s10549-017-4463-6. Epub 2017 Aug 22. Breast Cancer Res Treat. 2017. PMID: 28831670
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).
Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Sunami K, et al. Among authors: kogawa t. Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730. Cancer Sci. 2018. PMID: 30187675 Free PMC article.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Kogawa T, et al. Oncologist. 2020 Jun;25(6):e909-e919. doi: 10.1634/theoncologist.2018-0611. Epub 2020 Jan 31. Oncologist. 2020. PMID: 32003919 Free PMC article.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Doi T, Fujiwara Y, Shitara K, Shimizu T, Yonemori K, Matsubara N, Ohno I, Kogawa T, Naito Y, Leopold L, Munteanu M, Yatsuzuka N, Han SR, Samkari A, Yamamoto N. Doi T, et al. Among authors: kogawa t. Invest New Drugs. 2021 Feb;39(1):152-162. doi: 10.1007/s10637-020-00942-1. Epub 2020 Jun 20. Invest New Drugs. 2021. PMID: 32564277 Clinical Trial.
113 results